Introducing the science behind targeted treatments and immunotherapies for lung cancer

 

Format: This is a live, virtual event. Each morning’s content is split over three pre-recorded videos of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each video. The presentations will be available online for 30 days after the live event.

Description: Over the course of two mornings, Elaine will guide you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
The first morning’s focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.
The second morning is about cancer’s relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.
As ever, Elaine’s presentations are full of colourful and enlightening illustrations to help you make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a relatively limited understanding of cell biology are able to understand (if you don’t understand the relationship between DNA, genes and proteins, do look this up beforehand).

View the programme in PDF format for Wednesday 2nd September on targeted treatments

View the programme in PDF format for Thursday 3rd September on immunotherapy

Audience: This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer.

Cost: £50 for each morning

To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2921